

SNBTS Publications and R&D Grants: Annual Report 2007~2008

SNBTS Publications in Journals

Appleford NE, Wilson K, Houston F, Bruce LJ, Morrison A, Bishop M, Chalmers K, Miele G, Massey E, Prowse C, Manson J, Will RG, Clinton M, Macgregor I, Anstee DJ. Alpha-Hemoglobin stabilizing protein is not a suitable marker for a screening test for variant Creutzfeldt-Jakob disease. *Transfusion*. 2008 May 22. [Epub ahead of print]

Beattie LM, Harrison E. SAGM blood for neonatal large volume transfusion. *Transfusion Alternatives in Transfusion Medicine*. 2008; 10(1): 34-36

Bessos H, Fraser R, Seghatchian J. Scotblood 2007: Tackling local and global issues in transfusion medicine - Donor recruitment, effective use of blood, stem cell plasticity, and vCJD. *Transfus Apher Sci*. 2008; 38: 77-83.

Blest A, Roberts M, Murdock J, Watson D, Brunskill S. How often should a red blood cell administration set be changed while a patient is being transfused? A commentary and review of the literature. *Transfus Med*. 2008; 18(2): 121-33.

Brazma D, Grace C, Howard J, Melo JV, Holyoake T, Apperley JF, Nacheva EP. Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. *Genes, Chromosomes and Cancer*. 2007; 46(11): 1039-50.

Brunskill SJ, Prowse C, Garrioch M, Gill R, Hebert P, Thompson J, Hyde C, Stanworth S, Roberts D. Blood substitutes for avoiding allogeneic blood transfusion. (Protocol). *Cochrane Database of Systematic Reviews*. 2003; Issue 3. Art No: CD004894. DOI: 10.1002/14651858.CD004894. The Cochrane Library. 2008; Issue 1. The Cochrane Collaboration: John Wiley & Sons Ltd, 2008.

Cedzynski M, Nuytinck L, Atkinson APM, Swierzko AS, Zeman K, Szemraj J, Szala A, Turner ML, Kilpatrick DC. Extremes of L-ficolin concentration in children with recurrent infections are associated with single nucleotide polymorphisms in the FCN2 gene. *Clin.Exp.Immunol*. 2007: 150; 99-104.

Clark E, Connor S, Taylor MA, Hendry CL, Madhavan KK, Garden OJ, Parks RW. Perioperative transfusion for pancreaticoduodenectomy and its impact on prognosis in resected pancreatic ductal adenocarcinoma. *HPB (Oxford)*. 2007; 9(6): 472-477.

Clark P, Walker ID, Govan L, Wu O, Greer IA. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. *Br J Haematol*. 2008;140: 236-40

Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, Weinmann R, Holyoake TL. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. *Blood*. 2008;111: 2843-53.

Drummond MW, Balabanov S, Holyoake TL, Brummendorf TH. Concise review: Telomere biology in normal and leukemic hematopoietic stem cells. *Stem Cells*. 2007; 25(8):1853-61.Review.

Fagge TJ, Barclay GR, Stove GC, Stove G, Robinson MJ, Head MW, Ironside JW, Turner ML. Application of Atomic Dielectric Resonance Spectroscopy for the screening of blood samples from patients with clinical variant and sporadic CJD. *J Transl Med*. 2007; 5: 41.

Ferguson E, Prowse C, Townsend E, Spence A, Hilten Ja, Lowe K. Acceptability of blood and blood substitutes. *J Intern Med*. 2008; 263: 244-55.

Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM, Goldstone AH; Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. *Blood*. 2007; 109: 944-50.

Foster PR. Selection of spiking materials for studies on the clearance of agents of transmissible spongiform encephalopathy during plasma fractionation. *Biologicals*. 2008; 36(2): 142-3.

Foxcroft Z, Campbell K, Merieux Y, Urbaniak S, Brierley M, Rigal D, Ouwehand WH, Metcalfe P, 13th International Society of Blood Transfusion Platelet Immunology Workshop. Report on the 13th International Society of Blood Transfusion Platelet Immunology Workshop. *Vox Sang*. 2007; 93(4): 300-305.

Franklin IM, Dow BC, Jordan AD. Benefits of a blood donation archive repository: international survey of donor repository procedures and Scottish experiences. *Transfusion*. 2007; 47: 1172-9.

Franklin IM. Is there a right to donate blood? Patient rights; donor responsibilities. *Transfus Med*. 2007; 17:161-8.

Franklin IM. Blood transfusion and hepatitis C in the UK. *Lancet*. 2008 ; 371: 471.

Gallagher RCJ, Waterfall M, Samuel K, Turner ML. Blood donor derived dendritic cells and cytotoxic T-cells for specific fusion-gene adoptive immunotherapy *Vox Sang* 2007: 92: 351-60.

Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). *Blood*. 2008; 111: 1827-33.

Graham SM, Vass JK, Holyoake TL, Graham GJ. Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. *Stem Cells*. 2007; 25: 3111-20.

Gray A, Hearnshaw K, Izatt C, Kirwan M, Murray S, Shreeve K. Safe transfusion of blood and blood components. *Nurs Stand*. 2007; 21(51): 40-7.

Griffiths SD, Burthem J, Unwin RD, Holyoake TL, Melo JV, Lucas GS, Whetton AD. The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. *Mol Biotechnol*. 2007; 36: 81-9.

Hall AM, Shen C-R, Ward FJ, Rowe C, Bowie L, Devine A, Urbaniak SJ, Elson CJ, Barker RN (2007). Deletion of the dominant autoantigen in NZB mice with autoimmune haemolytic anaemia: effects on autoantibody and T-helper responses. *Blood* 2007; 110: 4511-7

Halsey C, Fisher C, Strathdee G, Gibson B, Holyoake T, Vyas P, Graham G. GATA-1 mutational analysis in chronic myeloid leukaemia. *British Journal of Haematology* 2007: 137: 375-6.

Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, MacGilchrist A, Ghandi MK, Swerdlow AJ, Crawford DH. Allogeneic cytotoxic T cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase II multicenter clinical trial. *Blood*. 2007; 110: 1123-31.

Heaney NB, Holyoake TL. What is new in chronic myeloid leukaemia? *Scottish Medical Journal*. 2007; 52: 36-41.

Heaney NB, Holyoake TL. Therapeutic targets in chronic myeloid leukaemia. *Hematol Oncol*. 2007; 25: 66-75. Review.

Hornsey VS, Drummond O, McMillan L, Morrison A, Morrison L, Macgregor IR, Prowse CV. Cold storage of pooled, buffy-coat-derived, leucoreduced platelets in plasma. *Vox Sang*. 2008 Apr 2. [Epub ahead of print]

Hornsey VH, McColl K, Drummond O, MacGregor IR, Prowse CV. Platelet storage in Fresenius/NPBI polyolefin and BTHC-PVC bags: a direct comparison. *Transfusion Medicine* 2007: *In press*

Hornsey V, McMillan L, Morrison A, MacGregor IR, Prowse CV. Leucoreduced, apheresis platelet concentrates frozen in 6% DMSO: in vitro testing of thawed components. *In press*

Jarvis L, Becker J, Tender A, Cleland A, Queiros L, Aquiar A, Azevedo J, Aprili G, Bressan F, Torres P, Nieto S, Ursitti A, Montoro J, Vila E, Ramada C, Saldanha J. Evaluation of the Roche cobas s 201 system and cobas TaqScreen multiplex test for blood screening: a European multicenter study. *Transfusion*. 2008 May 29. [Epub ahead of print]

Jones M, Peden AH, Prowse CV, Gröner A, Manson JC, Turner ML, Ironside JW, Macgregor IR, Head MW. In vitro amplification and detection of variant Creutzfeldt-Jakob disease PrP^{Sc}. *J Pathol*. 2007; 213: 21-6.

Jones M, Wight D, McLoughlin V, Norrby K, Ironside JW, Connolly JG, Farquhar CF, Macgregor IR, Head MW. An Antibody to the Aggregated Synthetic Prion Protein Peptide (PrP106-126) Selectively Recognizes Disease-Associated Prion Protein (PrP(Sc)) from Human Brain Specimens. *Brain Pathol*. 2008 May 26. [Epub ahead of print]

Jorgensen HG, Allen EK, Jordanides NE, Mountford JC and Holyoake TL. Nilotinib exerts equipotent anti-proliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. *Blood* 2007; 109: 4016-9.

Jørgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. *Biochem Soc Trans*. 2007; 35: 1347-51. Review.

Kanhai HH, Porcelijn L, Engelfriet CP, Reesink HW, Panzer S, Ulm B, Goldman M, Bonacossa I, Richard L, David M, Taaning E, Hedegaard M, Kaplan C, Kiefel V, Meyer O, Salama A, Morelatti F, Greppi N, Marconi M, Tassis B, Tsuno NH, Takahashi K, Oepkes D, Porcelijn L, Kanhai H, Osnes LT, Husebekk A, Killie MK, Kjeldsen-Kragh J, Zupanska B, Muñoz-Diaz E, Nogués N, Parra J, Urbaniak SJ, Cameron A. Management of alloimmune thrombocytopenia. *Vox Sang*. 2007; 93: 370-85.

Kilpatrick DC, Downing I, MacDonald SL, Turner ML. MBL really binds to healthy human cells! *Scand J Immunol*. 2007; 66: 599-600

Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ, Bhatia R. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. *Leukemia*. 2008; 22: 748-55

Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. *Blood*. 2008; 111: 2329-38.

Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y; IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. *Blood*. 2008; 111: 4022-8.

Legler TJ, Liu Z, Mavrou A, Finning K, Hromadnikova I, Galbiata S, Meaney C, Hultén MA, Crea F, Olsson ML, Maddocks DG, Huang D, Fisher SA, Sprenger-Haussels M, Soussan AA, van der Schoot CE. Workshop report on the extraction of foetal DNA from maternal plasma. *Prenat Diagn*. 2007; 27(9): 824-9

McClelland B. Clinical quality improvement information for transfusion practice. *Transfusion*. 2007; 47: 137S-141S
McLintock LA, Cook G, Holyoake TL, Jones BL, Kinsey SE, Jackson JH. High loading dose AmBisome® is efficacious and well tolerated in the management of invasive fungal infection in haematology patients. *The Hematology Journal*. 2007; 92; 572-3.

McRoberts RJ, Beard D, Walsh TS. A study of blood product use in patients with major trauma in Scotland: analysis of a major trauma database. *Emerg Med J*. 2007; 24: 325-9.

Morrison A. and MacGregor I.. Measurement of CD83 mRNA by real-time polymerase chain reaction to determine removal of dendritic cells by leucoreduction of whole blood. *Transf. Med*. 2007; 17: 175-181

Morrison A, Hornsey VS, Prowse CV, Macgregor IR. Use of the DiaMed Impact R to test platelet function in stored platelet concentrates. *Vox Sang*. 2007; 93: 166-72.

Mountford JC. Human embryonic stem cells: Origins, characteristics and potential for regenerative therapy. *Transfus Med*. 2008; 18: 1-12.

Nejentsev S, Howson Jm, Walker NM, Szeszko J, Field SF, Stevens HE, Reynolds P, Hardy M, King E, Masters J, Hulme J, Maier LM, Smyth D, Bailey R, Cooper JD, Ribas G, Campbell RD, Clayton DG, Todd JA; Wellcome Trust

Case Control Consortium, Burton Pr, Cardon Lr, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, Mccarthy MI, Ouwehand WH, Samani NJ, Donnelly P, Barrett JC, Davison D, Easton D, Evans D, Leung Ht, Marchini JL, Morris AP, Spencer Cc, Tobin Md; Uk Blood Services And University Of Cambridge Controls, Attwood AP, Boorman JP, Cant B, Everson U, Hussey JM, Jolley JD, Knight AS, Koch K, Meech E, Nutland S, Prowse CV, Et Al. Collier DA, Elkin A, Farmer A, Williamson R, McGuffin P, Young AH, Ferrier IN, Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. *Nature*. 2007;450: 887-92.

Nightingale M, Prowse C. BCSH: The specification and use of Information Technology (IT) systems in Blood Transfusion Practice. *Transfusion Medicine*. 2007; 17: 150. (Editorial)

O'Looney N, Burgess ST, Kwan MC, Ross AJ, Robb J, Forster T, Beattie JS, Ghazal P, Petrik J, Campbell CJ. Evaluation of a protein microarray method for immuno-typing erythrocytes in whole blood. *J Immunoassay Immunochem*. 2008;29:197-209

Peden AH, Head MW, Jones M, MacGregor I, Turner M, Ironside J. Advances in the development of a screening test for variant Creutzfeldt-Jakob disease. *Expert Opin Med Diagn*. 2008; 2(2): 207-219

Pellicano F, Holyoake TL. Stem cells in chronic myeloid leukaemia. *Cancer Biomark*. 2007;3:183-91. Review.

Petrik J, de Haas M, Denomme G, Scott M, Seghatchian J. Small world - advance of microarrays: current status and future trends. *Transfus Apher Sci*. 2007;36:201-6

Petrik J. The role of microarrays in diagnostics. *Hospital Healthcare Europe* 2008. *In press*.

Pickford WJ, Watson AJ, Barker RN. Different forms of helper tolerance to carcinoembryonic antigen: ignorance and regulation. *Clin Cancer Res*. 2007; 13: 4528-4537.

Pirie L, McClelland DB, Franklin IM; EU optimal blood use project partners and project management team. The EU optimal blood use project. *Transfus Clin Biol*. 2007; 14: 499-503.

Pirie E, Green J. Should nurses prescribe blood components? *Nurs Stand*. 2007; 21(39): 35-41.

Prowse C. Zero tolerance. *Transfusion*. 2007; 47: 1106-1109. (Editorial)

Prowse C. Transfusion and variant CJD: An update February 2007. *BBTS CPD Newsletter*. 2007; 20(May): 5-7.

Reesink HW, Engelfriet CP, Hyland CA, Coghlan P, Tait B, Wsolak M, Keller AJ, Henn G, Mayr WR, Thomas I, Osselaer JC, Lambermont M, Beaten M, Wendel S, Qiu Y, Georgsen J, Krusius T, Mäki T, Andreu G, Morel P, Lefrère JJ, Rebulla P, Giovanelli S, Butti B, Lecchi L, Mozzi F, Van Hilten JA, Zwaginga Jj, Flanagan P, Flesland O, Brojer E, Łętowska M, Akerblom O, Norda R, Prowse C, Dow B, Jarvis L, Davidson F, Kleinman S, Bianco C, Stramer SI, Dodd Ry, Busch MP. Biobanks of blood from donors and recipients of blood products. *Vox Sang*. 2008 94; 242-60

Saleh E, McClelland DB, Hay A, Semple D, Walsh TS. Prevalence of anaemia before major joint arthroplasty and the potential impact of preoperative investigation and correction on perioperative blood transfusions. *Br J Anaesth*. 2007; 99:801-8.

Shepherd P, Dhanapala C, Maguire C, White J, Drummond M, Holyoake T, Johson PRE. Successful use of national cancer registry data to monitor the effective use of Imatinib for treating CML. *Scottish Medical Journal* 2008: (*in press*).

Slight RD, Buell R, Nzewi OC, McClelland DB, Mankad PS. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. *J Cardiothorac Vasc Anesth*. 2008; 22: 47-52.

Slight RD, Ferguson R, Stirling D, McClelland DB, Mankad PS. Experience with sodium fluorescein flow cytometry in the determination of red cell volume. *Int J Lab Hematol*. 2008 Feb 12. [Epub ahead of print]

Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, Meyer S, Eden T, Dickinson AM, Mountford JC, Jorgensen HG, Soutar R and Brown R. Inactivation of HOXA cluster genes by hypermethylation is frequent in both myeloid and lymphoid malignancy is associated with poor prognosis and may promote loss of differentiation. *Clin Cancer Res*. 2007; 13:5048-55.

Sukati H, Watson HG, Urbaniak SJ, Barker RN. Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune Thrombocytopenic Purpura. *Blood* 2007; 109: 4528-38.

Todd JA, Walker NM, Cooper JD, et al. (WTCCC). Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. *Nat Genet.* 2007; 39: 857-64.

Tura O, Barclay GR, Roddie H, Davies J, Turner ML. Absence of a relationship between immunophenotypic and colony enumeration analysis of endothelial progenitor cells in clinical haematopoietic cell sources. *J Transl Med.* 2007; 5: 37.

Tura O, Barclay GR, Roddie H, Davies J, Turner ML. Optimal ex vivo expansion of neutrophils from PBSC CD34+ cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPO *Journal of Translational Medicine* 2007; 5: 53.

Turner ML. Managing the risk of transmission of vCJD by blood and tissues. *The Bulletin of the Royal College of Pathologists* 2007; 139: 10-12.

Urbaniak SJ, Prowse CV. BCSH guideline for blood grouping and antibody testing in pregnancy, June 2006. *Transfus Med.* 2007; 17: 251 (Editorial)

Urbaniak SJ. Noninvasive approaches to the management of RhD hemolytic disease of the fetus and newborn. *Transfusion.* 2008;48: 2-5. (Editorial)

Walker WS, Leaver HA. Immunologic and stress responses following video-assisted thoracic surgery and open pulmonary lobectomy in early stage lung cancer. *Thorac Surg Clin.* 2007; 17(2): 241-9

Walsh TS, Prowse C. BCSH guidelines for policies on alternatives to allogeneic blood transfusion. 1. Predeposit autologous blood donation and transfusion, August 2006. *Transfus Med.* 2007; 17: 353

Ward FJ, Hall AM, Cairns LS, Leggat AS, Urbaniak SJ, Vickers MA, Barker RN. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. *Blood.* 2008;111:680-7.

Watson D, Murdock J, Doree C, Murphy M, Roberts M, Blest A, Brunskill S. Blood transfusion administration – one- or two-person checks: which is the safest method? *Transfusion.* 2008; 48: 783-9.

Webert Ke, Cserti CM, Hannon J et al (2008) Proceedings of a Consensus Conference – Pathogen Inactivation: Making Decisions about New Technologies. *Transfusion Medicine Reviews* 2008; 22; 1-34 (c.f. pp9-11)

Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature.* 2007; 447: 661-78.

Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC), Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. *Nat Genet.* 2007; 39: 1329-37.

Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. *J Thromb Haemost.* 2008; 6: 62-9.

Zeggini, E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JRB, Raynor NW, Freathy RM, Barrett JC, Shields B, Morris AP, Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR, Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney ASF, The Wellcome Trust Case Control Consortium (WTCCC), McCarthy MI, Hattersley AT. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. *Science.* 2007; 316(1 June): 1336-1341. Erratum in: *Science.* 317: 1035-6.

Zou J, Hannier S, Cairns LS, Barker RN, Rees AJ, Turner AN, Phelps RG. Healthy individuals have Goodpasture autoantigen-reactive T cells. *J Am Soc Nephrol.* 2008 Feb;19(2):396-404.

SNBTS Publications in Books

Cardigan R, Prowse CV, Williamson LM. Processing and Components: Leucoreduction and Pathogen Reduction. In: Transfusion Microbiology. Barbara JAJ, Regan FAM, Contreras MC. (Eds). Cambridge: Cambridge University Press. 2008; Ch 19: 239-258

Cutler FJ, Green RHA, McClelland DBL. Transfusion of blood and blood products. In: Principles and Practice of Surgery (5th Edition). Garden OJ, Bradbury AW, Forsythe JLR, Parks RW. (Eds). Edinburgh: Churchill Livingstone. 2007; Ch 4: 38-50

Foster P, Bienek C. Fractionated Products. In: Transfusion Microbiology. Barbara JAJ, Regan FAM, Contreras MC. (Eds). Cambridge: Cambridge University Press. 2008; Ch 20: 259-304.

Kilpatrick DC. Clinical significance of mannan binding lectin and L-ficolin. In: Collagen-Related Lectins in Innate Immunity. Kilpatrick D. (Ed). Trivandrum-695 023, Kerala, India: Research Signpost. 2007; Ch 4: 57-84.

MacDonald SL, Kilpatrick DC. Collagen-related defence proteins as animal lectins. In: Collagen-Related Lectins in Innate Immunity. Kilpatrick D (Ed). Trivandrum-695 023, Kerala, India: Research Signpost. 2007; Ch 1: 1-16.

Petrik J, Robb JS. Microarrays and blood diagnostics. In: Bioarrays: From Basics to Diagnostics. Appasani K. (Ed). Totowa, NJ: Humana Press Inc. 2007; Ch 15: 215-230.

Petrik J. Microbiology Blood Testing and New Technologies. In: Transfusion Microbiology. Barbara JAJ, Regan FAM, Contreras MC. (Eds). Cambridge: Cambridge University Press. 2008; Ch 18: 227-238.

Petrik J. The role of microarrays in diagnostics. In: Hospital Healthcare Europe. 2007/08.

Pirie E. In: Clinical Nursing Practices (5th Edition). Jamieson EM, Whyte LA, McCall JM (Eds).

Prowse CV. Pathogen Inactivation of Blood Components. Chapter 11-E, in book "Alternatives to Blood Transfusion in Transfusion Medicine, 2nd Edition" Editors Maniatis A, Hardy J-F, van der Linden P. Publishers: Blackwells publishing. *In press*

Turner ML, Hewitt PE, Bruce M, Ironside JW. Prion Diseases. In: Transfusion Microbiology. Barbara JAJ, Regan FAM, Contreras MC. (Eds). Cambridge: Cambridge University Press. 2008; Ch 9: 141-147.

Walsh TS. Perioperative blood component therapy and haemostasis. In: The Year in Anaesthesia and Critical Care. Hunter, Cook, Priebe, Struys. (Eds). Oxford: Clinical Publishing. 2008;

SNBTS Correspondence

Cutler FJ, Niciu C, Murphy JA, Soutar RL. Use of TAGVHD warnings in patients receiving purine analogue chemotherapy. *Transfus. Med.* 2008; 18(2): 137-8.

Foster PR. Plasma fractionation in Scotland. *SNBTS Bloodletter.* 2008; Spring: 21-23

Franklin IM. Blood transfusion and hepatitis C in the UK. *Lancet.* 2008; 371: 471

Hughes M, Doig A, Soutar R. Solitary plasmacytoma and multiple myeloma: adhesion molecule and chemokine receptor expression patterns. *Br J Haematol.* 2007; 137(5): 486-7.

Laird J, Soutar R. Effective transfusion audit can improve and alter clinical practice: something that is often questioned. *Transfus. Med.* 2008; 18(2): 141-2

SNBTS Active Grants

Scottish Funding Council.

Wilmot I, Turner M, Illius A, Savill J. Strategic Development Grant for Centre of Regenerative Medicine. £2,030,000 (August 2006 to July 2010)

Medical Research Council

Holyoake TL, Brunton V. Koschmieder S. Is Bcr-Abl expression relevant for the survival of cancer stem cells in chronic myeloid leukaemia? £680,000. (June 2007 – May 2010)

European Union

SJ Urbaniak, SS Armstrong-Fisher, M Moss. Special non-invasive advances in fetal and neonatal evaluation network (SAFE). £113,195 (current share of 12 million euro) SAFE Fellow & PhD student. EU (Network of Excellence) (2004-2009)

Lowe K, Prowse CV et al Euroblood substitutes. 1,500,000 euros overall. SNBTS component £55,000 (years 2004-2007)

Franklin IM, Hart M, Arthur E, McClelland DBL, Pirie E The EU optimal blood use project. 890,285 Euros €500,000 (56.16% EC funded) (3 years 2007-2010)

Leukaemia Research Fund

Holyoake TL, Mountford J, Clark R Do transporter proteins contribute to clinical resistance to Imatinib in CML? A combined study in Liverpool and Glasgow correlating transporter expression and function with Imatinib uptake and efflux. £279,789. (£150,401 in Glasgow) (3 years October 2004 – September 2007).

Holyoake TL. FACS in studies of normal and malignant human and murine haemopoiesis. £142,233. (January 2005-December 2007).

Holyoake TL, Apperley J. LRF UK CML Biobank. £25,000. (2 years October 2005 – September 2007)

Holyoake TL. Irvine S. An investigation of proteasome activity and inhibition in chronic myeloid leukaemia stem cells. £116,024. (2 years January 2006 – December 2007)

Holyoake TL. Brunton V, Koschmieder S. Is Bcr-Abl expression relevant for the survival of cancer stem cells in chronic myeloid leukaemia? £28,221. (3 years January 2007 – December 2009)

Graham G, Holyoake TL. The role for CXCR2 ligands in haemopoietic stem cell mobilisation. £63,970. (August 2006 – July 2007)

British Heart Foundation

Barclay GR, Hadoke P, Mills N, Newby DE, Turner ML. Preclinical in vivo evaluation of potential sources of human endothelial progenitor cells for autograft cellular therapy of ischaemia. £239,930 (3 years July 2006 to June 2009).

Mills NL, Newby DE, Barclay GR, de Belder MA, Robinson SD. Endothelial progenitor cells in acute vascular injury and repair. £242,685 (3 years from August 2007)

Mountford J. Generation of cardiomyocytes from mesenchymal stem cells derived from adult human sternal bone marrow. (as Principal Investigator for Clinical Research Fellow funding) £149,478 (3 years from January 2005)

Chief Scientists Office.

P Newsome, D Harrison, ML Turner, L Forrester, J Pleveris, K Samuel, W Bickmore. In vivo study of hepatocytic differentiation of human haematopoietic stem cells and their reparative role in liver injury. £183,926 (3 years from July 2004 to June 2007).

Head MW, MacGregor I, Williamson A, Moroncini G, Turner M, Ironside J. Development of a conformation dependent immunoassay for the detection of abnormal prion protein in blood. £188,172 (2

years from July 2005 to June 2007)

De Sousa P, Head MW, Turner ML, Manson J. Proof of principle validation of a human embryo cell based screen for susceptibility to infectious prion transmission. £125,438. (August 2007 – December 2008).

Copland MC. Consumables £24,000. (3 years June 2006 - May 2009).

De Sousa P, Head M, Turner M, Manson J. Proof of principle demonstration of human embryo stem cell based detection of prions. £127,707 (18 months to June 2009).

Mountford J, Allan E & University of Glasgow staff Measurement and modulation of tyrosine kinase inhibitor drug levels in Chronic Myeloid Leukaemia £42,473 (12 months to February 2008)

Department of Health

Houston F, Prowse C, Turner M, MacGregor I, Hornsey V, Hunter N, Foster J, Groschup M. The effect of leucodepletion on transmission of BSE by transfusion of sheep blood components. £3,424,382 (6 years to December 2010.)

UK Department of Defence

Prowse C, Hornsey V. Validation of frozen Platelets in vitro. £7,650. (1 year to March 2008)

Navigant Inc.

Prowse C et al. Validation of riboflavin treated fresh frozen plasma. £52,310 . (1 year to July 2008)

Polish State Committee for Scientific Research

Swierzko AS, Szczapa J, Cedzynski M, Szemraj J, Domzalska-Popadiuk, I, Klink M, Kilpatrick D.C. Lectin pathway of complement in defence against infection in newborns. £21,000 (3 years May 2005-May 2008).

Cedzynski M, Atkinson APM, Swierzko AS, Szemraj J, MacDonald SL, Kilpatrick DC, Buczylo K, Zeman K. Investigation of the role of insufficiency of L-ficolin and other components of the lectin pathway of complement activation in recurrent respiratory infections in children with allergies. £26,000 (3 years April 2006- April 2009).

Novartis MTA

Holyoake TL, Jorgensen HG.. Study of the effects of AMN107 and imatinib on the viability of quiescent haematopoietic stem cells from normal and CML patients. £55,160. (2 years June 2005 – May 2007)

Iranian Government

SJ Urbaniak, RN Barker, M Moss. HPA-1a GP IIIa peptide binding and processing. (PhD studentship) £93,900. (from years 2003-2007)

SJ Urbaniak, SS Armstrong-Fisher. Identification of fetal DNA genetic markers in maternal plasma. (PhD Studentship) £91,400. (from years 2004-2008)

DiaMed AG

RH Fraser. Development of novel monoclonal blood grouping reagents (Research Assistant salary funding). 200,000 SFr £88,000 (Rolling grant from years 2004-2008)

NHS Grampian University Hospitals Division (GUHT) Endowments.

SJ Urbaniak. Research Technician funding. £36,000. (for years 2005-2008).

Nestech Partnership

SJ Urbaniak, L Cairns, RN Barker, E Rattray. Peptide immunotherapy to suppress antibodies to red blood cells. £203,875. (3 years from 2005-2008)

NHS National Services Scotland - Service Redesign Bid

SJ Urbaniak, SS Armstrong-Fisher. Pilot study of non-invasive RhD genotyping on maternal plasma. £56,480. (2 years 2006-2008)

NHS Blood and Tissues (England)

SS Armstrong-Fisher, SJ Urbaniak. Placental transfer of recombinant antibodies. £5,000. (2 years 2006-2008)

Friends of ANCHOR funds

SJ Urbaniak. Funding for purchase of Luminex equipment - £13,850 (in year 2007-08)

Glasgow & West of Scotland Blood Transfusion Association Donor Comfort & Research Fund.

A Mackie, RG Drake, DA Colligan, RH Fraser. Assessment of the potential for expression of Kell and Cellano protein on the surface of non-erythrocyte mammalian cells. £2,700 (in year 2007-08)

University of Bristol

SS Armstrong-Fisher, SJ Urbaniak. Fetal DNA genetic markers in maternal plasma. (Funding support of PhD Studentship) £15,000 (in year 2007-2008)

Scottish Enterprise Proof of Concept

M Moss, S Urbaniak. Blood group mimotopes. £248,945. (3 years 2008-2010)

Glasgow Royal Infirmary Endowments

Holyoake TL and Allan E. Targeting quiescent CML stem cell by combining G-CSF and imatinib mesylate £9,700 (6 years to January 2011)